# Apollo Hospitals vs Fortis Healthcare: A Strategic Deep Dive into India's Leading Hospital Networks

> This comprehensive investment thesis provides a comparative analysis of Apollo Hospitals and Fortis Healthcare, the two dominant players in India's private healthcare sector. The research evaluates their business models, management efficiency, and future growth trajectories while addressing critical risk factors and valuation scenarios. Investors will gain insights into which hospital chain is better positioned to capitalize on the rising demand for specialty medical services and healthcare infrastructure expansion.

**Companies**: Fortis Health., Apollo Hospitals
**Sectors**: Healthcare
**Published**: 2026-04-20
**Last Updated**: 2026-04-21
**Source**: https://thesisloop.ai/thesis/3d421348-9f44-44c2-a1f8-a2e890ff7b0e

## Score Overview

| Company | Management | Business Model | Future Growth | Risk |
|---------|-----------|---------------|--------------|------|
| Fortis Health. | 74/100 | 78/100 | 68/100 | 46/100 |
| Apollo Hospitals | 68/100 | 76/100 | 66/100 | 67/100 |

## Fortis Health. (BSE:532843)

**Sector**: Healthcare | **Industry**: Hospital

### Management Credibility

- **[CATALYST] M&A of Regional Hospital Chains** (POSITIVE, MET): The O&M agreement has been operationalized this quarter, with Fortis earning INR 5 crores in fees. (1 met across 1 tracked commitment)
  > In January 2026, the Company acquired the 125-bedded People Tree Hospital... enabling future expansion to over 300 beds.
- **[METRIC] Average Revenue Per Occupied Bed** (POSITIVE, MET): Hospital business ARPOB for Q2 FY26 was INR 2.51 Cr, representing a 5.8% growth YoY, which is exactly within the guided range. (1 met across 1 tracked commitment)
  > but we maintain our guidance that ARPOB growth should be in the -- in the normal course, it should be around 5%, 6%.
- **[METRIC] Bed Occupancy Rate** (NEGATIVE, MISSED): Hospital occupancy improved to 69% in Q1 FY26, trending towards the full-year target of 70-71%. (1 in progress, 1 met, 1 missed across 3 tracked commitments)
  > Vivek Goyal: Yes, we are aiming around 70%-71% occupancy level at the overall level because this brownfield expansion is on the existing facility and these hospitals anyway operating at 50% type of occupancy level.
- **[METRIC] New Bed Maturity Timeline** (POSITIVE, MET): The Manesar facility achieved EBITDA positive status in less than one year, ahead of previous expectations. (1 exceeded, 3 met across 4 tracked commitments)
  > I am expecting if we're able to achieve the revenue of INR2 crores more per month, which we are expecting in the next couple of months, this unit should be breakeven on EBITDA level.
- **[PRINCIPLE] Brownfield Expansion Over Greenfield for ROE** (NEUTRAL, REVISED): Management has updated the timeline for the remaining capacity addition at Manesar to Q4 FY26. 175 beds were added till Dec'25. (1 revised across 1 tracked commitment)
  > But at the same time, we are also going to expand and start the expansion work for creating further beds so that the capacity can be taken to 300 beds... So over the next 3 to 4 years, we should see this as a high-end 300-bedded super speciality hospital
- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (NEUTRAL): Fortis plans to install an oncology block at the Jaipur facility to improve margins and clinical offerings. — target: Oncology block installation
  > So these type of specialty takes some time. And generally, it is 18 to 24 months' time. So in the next year budget, we were planning to put something for Jaipur.
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (NEUTRAL, IN_PROGRESS): For the 9-month period, hospital business operating margins reached 22.2%. While slightly below the 22.5% stretch target, it shows significant improvement from 20% in the previous year. (2 in progress across 2 tracked commitments)
  > So I think there is a possibility we can see higher margin improvement than what we have guided at the beginning of the year. To quantify it will be a bit higher.
- **[TREND] Massive Capacity Addition Cycle** (NEUTRAL, REVISED): Management reported adding approximately 750 operational beds so far in FY26, significantly exceeding the initial full-year target of 400-500 beds due to aggressive inorganic growth. (1 exceeded, 2 revised, 1 met across 4 tracked commitments)
  > Neha Manpuria: Okay. And second -- and so we still maintain the full year addition of about 400, 500 beds? Ashutosh Raghuvanshi: That's correct. . Yes, that's right.
- **[TREND] Robotic and Minimally Invasive Surgery** (NEUTRAL): The company plans to add 4 new robotic machines across the network within the current year at a capex of approximately INR 12 crores per da Vinci unit. — target: 4 robotic machines
  > So we have approximately 15 robotic machines across our network right now, and we are in the process of getting another 4 this year.
- **[TREND] Tier-2/3 City Hospital Expansion** (NEUTRAL): Fortis has entered into an O&M agreement for a 550-bedded super specialty hospital to be constructed in Lucknow. — target: 550 beds
  > Aug’25 : Fortis entered into collaboration agreement for Operations and Management (O&M) of 550 bedded greenfield super specialty hospital to be constructed in Lucknow by the Ekana Group.
- The company has achieved a 300 basis point improvement in consolidated operating EBITDA margins for the 9-month period, surpassing the full-year target of 200 bps. (1 exceeded, 1 met across 2 tracked commitments) (POSITIVE, EXCEEDED)
  > As we have guided earlier also, it was -- the margins for -- if you see the half year, we are around 24%. So I think we'll be somewhere around the 23%, 24% for the whole year is what we are expecting.

### Business Model

- **[CATALYST] NABH Accreditation as Quality Differentiator** (NEUTRAL): Fortis maintains a high-quality clinical reputation evidenced by its 4 JCI and 33 NABH accredited facilities, which acts as a barrier to entry and a magnet for medical tourism.
  > 4 JCI Accredited; 33 NABH Accredited/ Certified
- **[CATALYST] M&A of Regional Hospital Chains** (POSITIVE, Change: EXPANDING): Fortis is deepening its cluster presence in Punjab through the acquisition of Shrimann Superspecialty Hospital, adding 228 beds with potential to reach 450. (4 expanding, 1 shifted)
  > Fortis signed definitive agreement in February 2025 to acquire Shrimann Superspecialty Hospital in Jalandhar, Punjab... This acquisition will add 228 beds to our network.
- **[METRIC] Average Revenue Per Occupied Bed** (POSITIVE, Change: EXPANDING): The hospital business remains the dominant engine, growing 14.8% for the full year FY25, driven by higher occupancy and ARPOB expansion. (2 expanding)
  > Hospital business revenues grew 14.8% to INR 6,528. Operating margins stood at 20.5% versus 18.6% in FY24.
- **[METRIC] Bed Occupancy Rate** (POSITIVE, Change: EXPANDING): The hospital business remains the primary engine, with revenue growing 14.8% and EBITDA margins expanding from 18.6% to 20.5% for the full year FY25. (2 expanding)
  > Our hospital business revenues have grown 14.8% to INR 6,528 crores... hospital business operating EBITDA margins have improved from 18.6% to 20.5% in financial year '25.
- **[METRIC] International Patient Revenue Mix** (POSITIVE, Change: EXPANDING): International patient revenue grew 21% YoY, maintaining a stable share of the hospital business at approximately 7.9%. (2 expanding, 3 stable)
  > So I mean the percentage of revenue, this has been stable at about 8%, 9% and somewhere as total revenue percentage. It has remained in that level, and it is likely to remain in that level.
- **[PRINCIPLE] Brownfield Expansion Over Greenfield for ROE** (POSITIVE, Change: EXPANDING): Fortis is aggressively expanding its scale through a planned addition of ~2000 beds by FY29, primarily through brownfield projects and the acquisition of Shrimann Hospital. (3 expanding)
  > We continue to progress on our brownfield expansion plans and are evaluating further inorganic opportunities in our existing clusters.
- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Change: EXPANDING): The hospital business is expanding through both organic growth and strategic acquisitions, with revenue growing 18.6% and margins expanding significantly due to a better specialty mix and robotic surgeries. (5 expanding across 1 engine)
  > Our hospital business revenues grew 19.4% to INR1,938 crores... The hospital business operating EBITDA margins have improved from 20% in quarter 3 of '25 to 21.7% in quarter 3 of financial year '26
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (POSITIVE, Change: EXPANDING): Operating EBITDA margins for the hospital business improved from 21.4% to 22.9%, reflecting better operating leverage despite a slight dip in occupancy from 72% to 71%. (1 expanding)
  > Operating EBITDA margin at 22.9% vs 21.4% in Q2 FY25
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Change: EXPANDING): The company is aggressively expanding its scale through brownfield additions (900 beds planned) and a new O&M agreement to manage 700 beds for Gleneagles India. (5 expanding)
  > 36 Healthcare Facilities; 6,000+ Operational Beds; 400 diagnostics labs.
- **[TREND] Medical Tourism Growing at 20%+ CAGR** (POSITIVE, Change: EXPANDING): International patient revenue grew 26% to INR 169 Cr, increasing its share of total hospital revenue from 7.7% to 8.1%, signaling strong recovery in medical tourism. (1 expanding)
  > International Patient revenues grew 26% to INR 169 Cr in Q2 FY26 vs INR 135 Cr in Q2 FY25. The business contributed to 8.1% to overall hospital business revenues
- The diagnostics business (Agilus) saw revenue growth of 4.0% for the year, with a significant margin expansion to 19.8% from 17.3%. (5 expanding across 1 engine) (POSITIVE, Change: EXPANDING)
  > the diagnostics business net revenue reported a growth of 7.3% to INR327 crores... Operating EBITDA margin gross revenue stood at 23.1% versus 14.4% in Q3 of financial year '25.

### Future Growth

- **[CATALYST] Ayushman Bharat Tariff Revision** (POSITIVE, Trend: NEW_TREND): Management reports positive early results from CGHS tariff revisions, though full impact is expected in FY27 as registration for super-specialty categories opens. (1 new trend across 1 signal)
  > So we have started seeing the positive result from the CGHS particularly. ECHS, the circular is new... But until now, the number is quite positive.
- **[CATALYST] M&A of Regional Hospital Chains** (POSITIVE, Trend: NEW_TREND): Fortis is aggressively pursuing inorganic growth in the Punjab region, acquiring Shrimann Superspecialty Hospital with potential to expand to 450 beds. (3 new trend across 3 signals, 1 leading indicator)
  > in January 2026, we acquired the 125-bedded People Tree Hospital in Yeshwanthpur, Bengaluru for INR430 crores... enables future expansion to over 300 beds within the same location.
- **[METRIC] Average Revenue Per Occupied Bed** (POSITIVE, Trend: STEADY): ARPOB growth is accelerating significantly, reaching INR 2.65 Crores per annum in Q1 FY26, a 10.2% increase compared to the previous year, driven by a better specialty mix and complex cases like robotic surgeries. (2 accelerating, 3 steady across 5 signals)
  > Our hospital business recorded a 4.5% increase in ARPOB, reaching INR2.56 crores per annum. The growth in ARPOB was supported by increase in share of complex cases reflected in, for instance, a 52% year-on-year increase in robotic surgeries.
- **[METRIC] International Patient Revenue Mix** (POSITIVE, Trend: ACCELERATING): International patient revenue is accelerating, growing 21% YoY in the most recent quarter, slightly higher than the previously reported 19% trend. (3 accelerating, 1 decelerating, 1 steady across 5 signals, 1 leading indicator)
  > International Patient revenues grew 19% to INR 156 Cr in Q3FY26 vs INR 132 Cr in Q3FY25.
- **[PRINCIPLE] Brownfield Expansion Over Greenfield for ROE** (NEUTRAL): Fortis is significantly expanding its bed capacity through brownfield projects (adding to existing hospitals) and acquisitions, aiming to reach over 1,500 beds in the Bengaluru market alone.
  > Our acquisition in Bengaluru enables us to strengthen our presence in this market from approximately 900 beds across seven facilities with a potential to scale up to over 1,500 beds in the future. We continue to progress on our brownfield expansion plans
- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Trend: ACCELERATING): High-value specialties are significantly outperforming the general business growth, with Oncology and Neurosciences contributing 62% of hospital revenues. (3 accelerating, 2 steady across 5 signals, 1 leading indicator)
  > Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 19% and contributed 61% to overall hospital business revenues.
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (NEUTRAL): Profitability is improving significantly as the company fills more beds, with hospital profit margins rising to 21.7% this quarter. — Hospital Operating EBITDA Margin: +170 bps YoY
  > The hospital business operating EBITDA margins have improved from 20% in quarter 3 of '25 to 21.7% in quarter 3 of financial year '26
- **[PRINCIPLE] Payor Mix Dictates Revenue Predictability** (NEUTRAL, Trend: STEADY): The impact of CGHS rate revisions is currently being evaluated. While management expects a positive impact on revenue, they are cautious about drug price restrictions and payment predictability (180-day cycle). (1 steady across 1 signal)
  > And our government payer where this particular CGHS also come is generally contributing 18% to 20% of our total overall revenue... Looking like it will be a positive impact.
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Trend: ACCELERATING): Fortis is entering a massive brownfield expansion cycle, planning to add approximately 2,000 beds from FY26 to FY29, with a significant 993-bed addition scheduled for FY26 alone. (5 accelerating across 5 signals, 2 leading indicators)
  > During the year so far, we have added approximately 750 operational beds... The bed addition also accounts for our Jalandhar acquisition, Greater Noida lease facility and expansion in our existing facilities
- **[TREND] Robotic and Minimally Invasive Surgery** (NEUTRAL): Fortis is investing in advanced medical technology, such as robotic surgical systems, to improve patient outcomes and attract more complex surgical cases.
  > Fortis Hospital, Manesar, launched the Da Vinci Xi Robotic Surgical System... Fortis Hospital, Nagarbhavi, Bengaluru, launched the next-generation Mako Robotic System for advanced knee joint replacement surgeries
- The diagnostic arm (Agilus) is seeing a recovery in margins and a shift toward preventive health. Preventive portfolio revenue grew 13% in FY25, now contributing 11% of total diagnostic revenue, up from 10% in the prior year. (5 accelerating across 5 signals, 1 leading indicator) (POSITIVE, Trend: ACCELERATING)
  > The revenue contribution from preventive portfolio has increased to 12% in Q3 from 10% in Q3 of '25, while the contribution from specialized portfolio has increased to 35% from 33%

### Risk Assessment

- **[CATALYST] Ayushman Bharat Tariff Revision** (POSITIVE): The trajectory is easing for CGHS as positive results are appearing, but ECHS remains uncertain due to lack of clarity on drug pricing and new circulars. (1 easing)
  > So we have started seeing the positive result from the CGHS particularly. ECHS, the circular is new, and there is still some doubts which need to be cleared.
- **[CATALYST] M&A of Regional Hospital Chains** (NEUTRAL): The integration is now progressing well under a new operation and management services agreement for five hospitals and a clinic. Management expects to eventually evaluate a full merger/integration. (1 easing, 1 intensifying)
  > The integration of Gleneagles units under the agreement with Fortis is progressing well.
- **[METRIC] Bed Occupancy Rate** (NEUTRAL, Risk: LOW): The BG Road facility is struggling with low patient occupancy, which acts as a drag on the overall hospital segment performance. [EXECUTION]
  > Except I will say BG Road, which is still struggling. And we are working on how to improve the occupancy level of BG Road.
- **[METRIC] International Patient Revenue Mix** (NEUTRAL, Risk: LOW): International patient revenue is vulnerable to unpredictable global political situations, making it a risky segment to rely on for steady growth. [DEMAND]
  > Because the international traffic is subject to so many other geopolitical situations, which are continuously evolving right now, so I think one cannot really bank on that.
- **[METRIC] New Bed Maturity Timeline** (NEGATIVE, Risk: MODERATE): Management reported a 3-month delay in the FMRI capacity addition, pushing commissioning to the end of March (next financial year). However, 550 operational beds were successfully added in H1 FY26. (2 intensifying, 1 easing, 2 stable)
  > Neha, so we have this facility, as Vivek had said earlier, is running sub-optimally at the moment. So it needs to be brought to Fortis standards. It would require some investment in that regard.
- **[PRINCIPLE] Brownfield Expansion Over Greenfield for ROE** (NEUTRAL, Risk: MODERATE): Management confirms they are on track to add 900 beds this year. The acquisition of Shrimann Hospital (228 beds) is already consummated, and brownfield expansions at FMRI, Noida, and Faridabad are progressing with expected operationalization of 50% of new capacity within the current fiscal year. (2 stable)
  > Our acquisition in Bengaluru enables us to strengthen our presence in this market from approximately 900 beds across seven facilities with a potential to scale up to over 1,500 beds in the future. We continue to progress on our brownfield expansion plans
- **[PRINCIPLE] Doctor Ecosystem Is Competitive Moat** (NEUTRAL, Risk: MODERATE): While specific 'Gleneagles' branding was not the focus, management highlighted that they have successfully acquired the 'Fortis' brand and trademarks, which removes the royalty drag and provides brand stability. However, some facilities like Vashi still face clinician attrition issues. (1 stable, 1 easing, 1 intensifying)
  > Nine months growth is actually negative for the unit we are looking at. It is almost 4% negative. And there are a lot of disturbance. There is clinician attrition.
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (POSITIVE): The Manesar facility is showing strong recovery. It is currently at 40% occupancy with only 90 beds commissioned; management expects to reach breakeven even before hitting 50% occupancy, which is targeted by year-end. (1 easing)
  > Regarding Manesar... The exit should be at least 50%-plus occupancy. I think so. Even before that, we should expect a breakeven.
- **[PRINCIPLE] Payor Mix Dictates Revenue Predictability** (POSITIVE, Risk: MODERATE): The share of institutional/government business (which typically has lower rates) decreased slightly to 20.3% from 20.9%. International business (high margin) grew 21%, helping to balance the payor mix and reduce reliance on lower-paying domestic schemes. (1 easing, 4 stable)
  > Similarly, ECHS also, there is a lot of confusion about the drug pricing and things like that. And there, a lot of clarity team is asking.
- **[TREND] Massive Capacity Addition Cycle** (NEGATIVE): The risk is stable as the company has formalized a massive expansion plan of ~2,000 beds through FY29. While the Manesar facility is operationalizing (38% occupancy on 77 beds), the acquisition of Shrimann Hospital adds 270-450 beds to the execution pipeline. (2 stable, 1 intensifying)
  > Planned capacity addition of ~2000 beds* from FY26 to FY29... ramp up of operational beds will be done as per the business growth and occupancy trends
- Net debt has increased further to INR 1,869 Cr from INR 1,694 Cr in the previous quarter (March 2025). The Net Debt to EBITDA ratio has risen to 0.92x compared to 0.22x a year ago, driven by the acquisition of the 31.5% stake in Agilus Diagnostics and the 'Fortis' brand. (3 intensifying, 2 easing, 2 high-severity) (NEGATIVE, Risk: HIGH)
  > The decline in PAT was primarily due to the one-off expense for the quarter INR55 crores pertaining to New Labour Codes

### Scenario Analysis

- Fortis Healthcare faces a peripheral link to the Iran conflict primarily through second-order inflationary pressures on operational costs, such as energy-intensive hospital utilities and medical supply chain logistics. While these macroeconomic spillovers can impact margins, the conflict does not fundamentally alter the company's core healthcare delivery model, demand drivers, or competitive moat. (NEUTRAL)
- The adoption of AI-powered surgical systems and diagnostic tools is driving a structural shift in Fortis's case mix toward high-complexity tertiary care. This first-order automation of clinical workflows is leading to a second-order expansion in ARPOB (Average Revenue Per Occupied Bed) and a growing data advantage through digital patient engagement. Ultimately, this creates a third-order competitive moat that shields the company from business model obsolescence while consolidating its position as a high-end technology leader in the Indian healthcare market. (POSITIVE)
  > So AI is a new theme, and health care, there are a lot of use cases for AI, and we are also working on some of the use cases. And we are taking help of our parent company, IHH. They are slightly more advanced in AI. So we are taking help from them, and I think you will see much more replication of A

## Apollo Hospitals (BSE:508869)

**Sector**: Healthcare | **Industry**: Hospital

### Management Credibility

- **[CATALYST] M&A of Regional Hospital Chains** (NEUTRAL, IN_PROGRESS): The composite scheme involving the amalgamation of Keimed and the restructuring of the pharmacy business is underway to achieve the 100% ownership structure. (1 in progress across 1 tracked commitment)
  > Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros
- **[METRIC] New Bed Maturity Timeline** (NEUTRAL): The company expects EBITDA losses from the six new hospitals to be approximately INR 150 crore in the next fiscal year. — target: INR 150 crore (+1 more commitment)
  > We continue to believe that next year, overall EBITDA losses from these hospitals should be around the INR 150 crore number, which is what would be the EBITDA losses from these hospitals
- **[PRINCIPLE] Brownfield Expansion Over Greenfield for ROE** (NEUTRAL): Management plans to renovate several existing Apollo Spectra centers in the final quarter of the fiscal year.
  > Spectra: ~5% YoY revenue growth in 9M FY26. Renovation planned for few existing centers in Q4
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (NEUTRAL): The internal target for hospital business EBITDA margins is to increase them by 500 basis points from the current base. — target: 500 basis points increase
  > And clearly, we would, the internal target is to take it higher by 500 basis points.
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, MET): The company successfully operationalized a 30-bed facility in Defence Colony, Delhi, which is part of the AHLL network expansion. (1 met across 1 tracked commitment)
  > To add 4,400 capacity beds ~3,600 census beds over the next 5 years
- **[TREND] Insurance Penetration Accelerating** (NEUTRAL): The company is expanding its insurance business across brands, products, and cities through recruitment and tech enablement.
  > Expanded the Insurance business across brands, products, cities, along with network growth driven by recruitment and tech enablement.
- **[TREND] Medical Tourism Growing at 20%+ CAGR** (NEUTRAL): Management targets a 30% organic growth trajectory for the hospital business, supported by the recovery of the Bangladesh market and expansion into new international territories. — target: 30%
  > Yes. I think we are quite confident that we will get back into 30%. We say this because Bangladesh, at least 60% has started coming back in October and we believe that we will mitigate the impact of losing one territory. Also, we are exploring new markets, including the Northern markets in Uzbekista
- Digital losses narrowed to INR 71 crore in Q2 FY26 from INR 101 crore in Q2 FY25, showing significant progress toward the breakeven target. (3 in progress across 3 tracked commitments) (POSITIVE, IN_PROGRESS)
  > Target to achieve EBITDA breakeven for digital business in next 4 quarters

### Business Model

- **[CATALYST] M&A of Regional Hospital Chains** (POSITIVE, Change: SHIFTED): Apollo HealthCo is being restructured through a composite scheme of arrangement to demerge its omnichannel pharmacy distribution and digital health platform into a new listed entity ('New Co'). This entity will also merge with Keimed to create India's largest pharma distributor. The proforma revenue for this combined segment is estimated at INR 16,267 Cr for FY25, with a target to reach INR 25,000 Cr by FY27. (1 shifted)
  > Creates a formidable Listed Omni channel Pharmacy distribution and Digital health platform leader in India with a scale of INR ~16.3k Cr (~US$ 1.9 bn) in Revenues in FY25 with stated plans to achieve ~ Rs25k Cr (~US$ 3 bn) Revenue run-rate estimated by end FY27
- **[METRIC] Average Length of Stay** (POSITIVE, Change: EXPANDING): Average Length of Stay (ALOS) dropped by 7% due to the adoption of new technologies like robotics and digital command centers, which improves bed turnover and efficiency. (1 expanding)
  > ALOS has dropped by 7%... the use of new technologies, whether it is the cardiac where we have minimally resistant or robotics. So, this is really driving down ALOS and allowing us to discharge patients much faster.
- **[METRIC] Average Revenue Per Occupied Bed** (POSITIVE, Change: EXPANDING): The core hospital business continues to expand through increased clinical intensity and pricing power, with revenue growing 14% and EBITDA margins improving from 24.1% to 24.8%. Growth was driven by an 11% increase in Average Revenue Per Inpatient (ARPP). (1 expanding)
  > 6 Metros Operating Beds 4,581 Occupancy 71% ARPP -IP 208,477 ROCE 31%
- **[METRIC] Bed Occupancy Rate** (POSITIVE, Change: EXPANDING): Healthcare Services revenue grew 11% YoY, though slightly slower than the previous 14% growth rate. Occupancy dipped to 65% from 68% in the prior year, partly due to a 1.5% revenue impact from fewer patients from Bangladesh. (1 expanding)
  > Healthcare Services Revenue grew by 11% in Q1FY26 (Inpatient Volume grew by 3% ; Price of and case mix of 8%)
- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Change: EXPANDING): Healthcare Services revenue grew 9% YoY in Q2 FY26, reaching ₹31,690 million. Growth was driven by a 2% increase in inpatient volumes and a 7% improvement in price/case mix. However, margins slightly contracted by 22 basis points due to a higher base of seasonal admissions in the previous year. (2 expanding across 1 engine)
  > Healthcare Services Revenue 31,832 Growth YoY(%) 14% EBITDA Margin 24.8%
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Change: EXPANDING): Apollo is aggressively expanding its scale with a plan to add 4,300 capacity beds over the next 5 years, representing a ~38% increase from current census levels. (4 expanding)
  > Largest Pan India Hospital Chain... Overall Total 76 Hospitals 10,325 Capacity Census Beds
- The company's scale is expanding significantly through the merger with Keimed, which has >2x the scale of its nearest competitor. The combined entity will serve 75k+ pharmacies and 3k+ hospitals, significantly strengthening its procurement and distribution moat. (5 expanding across 2 engines) (POSITIVE, Change: EXPANDING)
  > Total HealthCo Revenue 28,274 Growth YoY(%) 20% EBITDA Margin 4.5%

### Future Growth

- **[METRIC] Average Revenue Per Occupied Bed** (POSITIVE, Trend: ACCELERATING): Average Revenue per Inpatient (ARPP) grew by 9% YoY to ₹172,282, driven by an 8% improvement in price and case mix. This indicates a steady upward trajectory in clinical complexity and pricing power. (1 steady, 1 accelerating across 2 signals)
  > Average Revenue per In patient grew by 11% to Rs 180,917 in Q3FY26
- **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Trend: ACCELERATING): ARPP is accelerating, showing a 9% YoY growth in Q2 FY26 compared to the previous year, driven by a 14% increase in revenue from high-complexity 'CONGO' specialties. (1 accelerating, 1 steady across 2 signals)
  > Average Revenue per In patient grew by 9% to ₹ 173,318 in Q2FY26... partly offset by 14% increase in Revenue from CONGO Specialties.
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (POSITIVE, Trend: ACCELERATING): The company is targeting a significant margin expansion for the merged entity, moving from a proforma 3.5% in FY25 to a 7% exit run-rate by FY27, driven by digital business breakeven and supply chain efficiencies. (4 accelerating, 1 steady across 5 signals)
  > Consolidated EBITDA(Post Ind AS) 9,653... Growth YoY(%) 27%... Margin 14.9%
- **[PRINCIPLE] Payor Mix Dictates Revenue Predictability** (POSITIVE, Trend: STEADY): The company is deepening its insurance integration with 9 insurance provider tie-ups already established on the digital platform to improve revenue predictability. (1 new trend, 3 steady across 4 signals)
  > Inpatient Payor Mix: Insurance 45%
- **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Trend: ACCELERATING): Apollo has formalized a massive expansion plan to add 4,372 total beds (3,577 census beds) over the next 5 years, targeting a total capacity of ~13,000 census beds. This is a significant acceleration in planned capacity addition compared to previous maintenance cycles. (2 accelerating, 2 steady across 4 signals, 1 leading indicator)
  > To add 4,400 capacity beds ~3,600 census beds over the next 5 years... Total Project Cost of ~Rs 8,200crs
- **[TREND] Insurance Penetration Accelerating** (POSITIVE, Trend: STEADY): The shift toward insurance is a steady trend, with insurance now representing the largest single payor category at 45%, up from 40% for self-pay. (1 steady across 1 signal)
  > Inpatient Payor Mix: Insurance 45%, Self Pay 40%
- **[TREND] Robotic and Minimally Invasive Surgery** (NEUTRAL): Apollo is investing in high-end medical technology, such as robotic surgery centers, to attract patients needing specialized care.
  > Apollo Spectra Hospital, Delhi launched an advanced multi-robot surgery centre equipped with cutting-edge robotic systems
- **[TREND] Tier-2/3 City Hospital Expansion** (POSITIVE, Trend: STEADY): The offline pharmacy network has reached a massive scale of 6,626 stores across 1,200 cities, maintaining a steady expansion pace to become India's largest organized pharmacy platform. (1 steady across 1 signal, 1 leading indicator)
  > Varanasi, U.P Greenfield 400 beds... Lucknow (Expansion), U.P Brownfield 200 beds
- The Apollo 24|7 digital platform reached 41 million registered users, with Daily Active Users (DAU) growing 55% YoY to 7.9 Lakh. While the total user base is slightly lower than the 46Mn target mentioned in other periods, the engagement metrics (DAU) are accelerating sharply. (3 accelerating, 1 decelerating, 1 steady across 5 signals, 2 leading indicators) (POSITIVE, Trend: ACCELERATING)
  > Diagnostics Revenue 1,768... Growth Revenue 46%

### Risk Assessment

- **[METRIC] Bed Occupancy Rate** (NEGATIVE): The risk is intensifying as occupancy rates fell further to 65% in Q1FY26 from 68% in Q1FY25. (3 intensifying, 1 stable)
  > Occupancy Q1FY26 65% Q1FY25 68%
- **[METRIC] International Patient Revenue Mix** (POSITIVE): The risk is easing as management reports that international patients from Bangladesh (a key driver for Northern/Metro hubs) began returning in October, and they are diversifying into new markets like Uzbekistan and Africa. (1 easing)
  > Bangladesh, at least 60% has started coming back in October and we believe that we will mitigate the impact of losing one territory. Also, we are exploring new markets, including the Northern markets in Uzbekistan, etcetera.
- **[PRINCIPLE] Occupancy Is Primary Margin Lever** (NEUTRAL, Risk: MODERATE): The company's occupancy rates have slightly declined compared to the previous year, meaning expensive hospital beds are sitting empty more often, which hurts profit margins. [MARGIN_COST]
  > Occupancy 67% (Q3FY26) vs 68% (Q3FY25)
- **[TREND] Massive Capacity Addition Cycle** (NEGATIVE, Risk: HIGH): The expansion risk remains high but stable as the company maintains its target to add ~3,577 census beds over the next 5 years with a total project cost of ~₹ 7,603 crs. The balance to be spent is ₹ 5,400 crs. (2 stable, 2 intensifying, 1 high-severity)
  > Total Project Cost of ~₹ 8,200crs with Balance to be spent of ~₹5,400crs. To add 4,400 capacity beds ~3,600 census beds over the next 5 years
- The risk is intensifying as the restructuring has entered a more complex phase with the approval of a 'Composite Scheme' involving the demerger of pharmacy distribution and amalgamation of Keimed. (5 intensifying) (NEGATIVE, Risk: MODERATE)
  > Consol Gross Debt 28,614

### Scenario Analysis

- Apollo Hospitals operates primarily as a domestic healthcare provider in India, with a business model driven by patient volume, clinical outcomes, and domestic insurance penetration. While an Iran conflict could indirectly influence input costs through energy-driven inflation or supply chain disruptions for imported medical equipment, these effects are peripheral and do not fundamentally alter the company's core service delivery or competitive moat. (NEUTRAL)
- Apollo’s adoption of the Clinical Intelligence Engine and AI-driven robotics (First Order) is directly reducing patient length of stay and increasing surgical precision. This leads to higher clinical intensity and improved revenue per patient (Second Order), as evidenced by the 11% ARPOB growth. Ultimately, these efficiencies and the massive data harvested from 46 million users create a structural 'data moat' (Third Order), positioning Apollo as the dominant aggregator in a consolidated Indian healthcare market. (POSITIVE)
  > Full stack digital healthcare platform • First-in-class AI enabled technologies including India’s first Clinical Intelligence Engine

---
*Generated by [ThesisLoop](https://thesisloop.ai) — AI investment research for Indian equities.*